Provided by Tiger Fintech (Singapore) Pte. Ltd.

Palisade Bio Inc.

1.07
+0.07007.00%
Volume:87.24M
Turnover:129.43M
Market Cap:5.13M
PE:-0.20
High:1.90
Open:1.49
Low:0.9800
Close:1.00
Loading ...

BRIEF-Palisade Bio Reports 100% Response in Phase 1b Ulcerative Colitis Trial of PALI-2108

Reuters
·
Yesterday

Palisade Bio Inc - Pali-2108 Safe and Well Tolerated With No Serious Adverse Events

THOMSON REUTERS
·
Yesterday

Palisade Bio Reports 100% Clinical Response in Phase 1B Ulcerative Colitis Cohort With Novel Pde4 Inhibitor, Pali-2108

THOMSON REUTERS
·
Yesterday

Palisade Bio Inc - to Submit Ind for Phase 2 Study in H1 2026

THOMSON REUTERS
·
Yesterday

Palisade Bio Reports 100% Clinical Response in Phase 1b Ulcerative Colitis Cohort with Novel PDE4 Inhibitor, PALI-2108

GlobeNewswire
·
Yesterday

BRIEF-Palisade Bio Inc Receives China Patent Allowance For Pali-2108

Reuters
·
31 Jul

Palisade Bio Inc - Patent for Pali-2108 Extends to 2045 in China

THOMSON REUTERS
·
31 Jul

Palisade Bio Receives Notice of Allowance for Composition of Matter Patent Covering Lead Product Candidate PALI-2108 in China

GlobeNewswire
·
31 Jul

Palisade Bio’s Phase 1 Study on PALI-2108: A New Hope for Ulcerative Colitis Treatment

TIPRANKS
·
31 Jul

Palisade Bio Inc. Announces $3.9 Million Private Placement Through Warrant Exercise

Reuters
·
25 Jul

Palisade Bio Inc. Files Initial Statement of Beneficial Ownership for Director Emil Chuang

Reuters
·
18 Jul

Palisade Bio appoints to its Board of Directors

TIPRANKS
·
09 Jul

Palisade Bio Inc. Appoints Emil Chuang to Board of Directors to Strengthen Clinical Strategy in Autoimmune and Inflammatory Diseases

Reuters
·
09 Jul

Palisade Bio’s PALI-2108: Promising Phase 1 Results and Strategic Positioning Drive Buy Rating

TIPRANKS
·
17 May

Palisade Bio Is Maintained at Buy by Brookline Capital

Dow Jones
·
14 May

Palisade Bio Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
13 May

Palisade Bio Q1 EPS $(0.47) Beats $(0.70) Estimate

Benzinga
·
13 May

Palisade Bio Inc expected to post a loss of 70 cents a share - Earnings Preview

Reuters
·
09 May

Palisade Bio Inc. Receives Nasdaq Notice for Non-Compliance with Minimum Bid Price Requirement

Reuters
·
03 May

Palisade completes dosing in Phase 1b portion of Phase 1a/1n study of PALI-2108

TIPRANKS
·
09 Apr